Skip to main content
Signal8
Launch Terminal

Vaxcyte, Inc. (PCVX)

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Vaxcyte, Inc. logo

Vaxcyte, Inc.

NASDAQ:PCVXHealthcare
-0.93%$62.03
AH$61.99-0.06%vs close
Mkt Cap$9.76B
Float130.56M
O/S157.39M
Vol
$ Vol
RVOL
Inst Own-
SI11.2%
Earnings
Dilution
Vaxcyte, Inc. logoNASDAQ:PCVX$62.03-0.93%
Phase Distribution
9 lead-sponsored trials·4 active·5 completed
Phase 11
Phase 1/22
Phase 23
Phase 33
Status Overview
Recruiting1
Active, not recruiting3
Completed5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Completed

    Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

    31 valent pneumococcal conjugate vaccine, PCV20

    Pneumococcal Disease

    Enrollment
    4,049
    Start
    Dec 2025
    Primary Completion
    Sep 2026
    Completion
    Sep 2026
    NCT07284654
  • Phase 3
    Active, not recruiting

    A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

    31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)

    Pneumococcal Vaccines

    Enrollment
    1,390
    Start
    Jan 2026
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT07365826
  • Phase 3
    Active, not recruiting

    Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

    31-valent pneumococcal conjugate vaccine, PCV20

    Pneumococcal Vaccines

    Enrollment
    752
    Start
    Feb 2026
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT07425392
  • Phase 2
    Completed

    Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

    24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine

    Pneumococcal Vaccines

    Enrollment
    207
    Start
    Jun 2022
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT05297578
  • Phase 2
    Completed

    Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

    0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20

    Pneumococcal Vaccines

    Enrollment
    802
    Start
    Mar 2023
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT05844423
  • Phase 2
    Active, not recruiting

    A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

    0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31

    Pneumococcal Vaccines

    Enrollment
    900
    Start
    Nov 2024
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT06720038
  • Phase 1/2
    Completed

    Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

    24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine

    Pneumococcal Vaccines

    Enrollment
    835
    Start
    Feb 2022
    Primary Completion
    Jan 2023
    Completion
    Jan 2023
    NCT05266456
  • Phase 1/2
    Completed

    Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

    31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine

    Pneumococcal Vaccines

    Enrollment
    1,015
    Start
    Nov 2023
    Primary Completion
    Jul 2024
    Completion
    Jul 2024
    NCT06151288
  • Phase 1
    Recruiting

    A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults

    Placebo, VAX-A1 Low

    Group A Streptococcal Infection

    Enrollment
    80
    Start
    Jun 2026
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT07616934
Search ClinicalTrials.gov for “Vaxcyte”